Browse the full directors' dealings record of Mentor Capital, Inc., a publicly traded company based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Mentor Capital, Inc. has published 4 public disclosures. Market capitalisation: €1.7m. The latest transaction was reported on 11 January 2022 — X. Among the most active insiders: Billingsley Chester. All data is accessible without an account.
4 of 4 declarations
Mentor Capital, Inc. (MNTR) is a U.S.-based micro-cap currently trading on the OTCQB market in the United States, rather than on NYSE or NASDAQ. For French-speaking investors evaluating the name, MNTR is best understood as an unusual special-situation issuer: part investment vehicle, part financing platform, and part asset-monetization company. According to the company’s own disclosures, Mentor Capital provides owners of businesses and pre-IPO companies with access to liquidity and funding from public sources and through the divestiture of legacy assets. Its business address is in Plano, Texas, while the company also describes its origins as an investment partnership formed in Silicon Valley by the current CEO in 1985, later incorporated in California in 1994 and subsequently redomiciled to Delaware. The operating profile is highly unconventional. Over time, Mentor Capital has been associated with a shifting set of investment themes and legacy holdings, including exposure to healthcare-related assets and, more recently, energy assets. Rather than building a single scaled operating franchise, the company appears to focus on capital allocation, asset sales, portfolio reshaping, and transaction execution. That means the investment case is driven less by classic operating KPIs and more by balance sheet decisions, asset realizations, and corporate events. For analysts, this is important: MNTR behaves more like a catalyst-driven small cap than a standard healthcare or industrial company. From a competitive standpoint, Mentor Capital is not a mainstream listed healthcare operator, despite being placed broadly in the Santé & Pharma bucket for classification purposes. Its market position is that of a very small, thinly traded U.S. issuer with limited scale, a niche shareholder base, and an externally visible focus on liquidity creation. This makes the stock more sensitive to disclosure quality, insider activity, and event-driven developments than to recurring revenue momentum. Recent corporate developments reinforce that picture. SEC records show a series of Form 4 insider transaction filings, highlighting ongoing changes in beneficial ownership and insider-related activity. The company also filed its annual 10-K in April 2026 and an 8-K shortly afterward, indicating active reporting. In addition, Mentor Capital disclosed in spring 2025 that its preferred shares were backed by gold bullion and that it added more interests in Permian Basin oil and gas assets, including royalty-related opportunities. Those announcements suggest the portfolio remains centered on tangible or transactionable assets rather than a single operating business line. For investors in France, Belgium, or Switzerland, MNTR should therefore be treated as a speculative U.S. small-cap special situation with high execution risk, limited liquidity, and potentially meaningful upside only if management continues to monetize assets and structure transactions successfully.